Referencias:
1Libby P. The molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-2850
CrossRef | Web of Science | Medline
2Arbab-Zadeh A, Nakano M, Virmani R, Fuster V. Acute coronary events. Circulation 2012;125:1147-1156
CrossRef | Web of Science | Medline
3Crea F, Liuzzo G. Pathogenesis of acute coronary syndromes. J Am Coll Cardiol 2013;61:1-11
CrossRef | Web of Science | Medline
4Falk E, Nakano M, Benton JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists' view. Eur Heart J 2013;34:719-728
CrossRef | Web of Science | Medline
5Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011;364:226-235[Erratum, N Engl J Med 2011;365:2040.]
Free Full Text | Web of Science | Medline
6Hoffmann U, Moselewski F, Nieman K, et al. Noninvasive assessment of plaque morphology and composition in culprit and stable lesions in acute coronary syndrome and stable lesions in stable angina by multidetector computed tomography. J Am Coll Cardiol 2006;47:1655-1662
CrossRef | Web of Science | Medline
7Motoyama S, Sarai M, Harigaya H, et al. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol 2009;54:49-57
CrossRef | Web of Science | Medline
8Narula J, Garg P, Achenbach S, Motoyama S, Virmani R, Strauss HW. Arithmetic of vulnerable plaques for noninvasive imaging. Nat Clin Pract Cardiovasc Med 2008;5:Suppl 2:S2-S10
CrossRef | Web of Science | Medline
9Schoenhagen P, Stone GW, Nissen SE, et al. Coronary plaque morphology and frequency of ulceration distant from culprit lesions in patients with unstable and stable presentation. Arterioscler Thromb Vasc Biol 2003;23:1895-1900
CrossRef | Web of Science | Medline
10Glagov S, Weisenberg E, Zarins C, Stankunavicius R, Kolletis G. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:1371-1375
Full Text | Web of Science | Medline
11Clarkson TB, Prichard RW, Morgan TM, Petrick GS, Klein KP. Remodeling of coronary arteries in human and nonhuman primates. JAMA 1994;271:289-294
CrossRef | Web of Science | Medline
12Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006;355:2395-2407
Free Full Text | Web of Science | Medline
13Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-1516
Free Full Text | Web of Science | Medline
14Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005;111:3481-3488
CrossRef | Web of Science | Medline
15Yonetsu T, Kakuta T, Lee T, et al. In vivo critical fibrous cap thickness for rupture-prone coronary plaques assessed by optical coherence tomography. Eur Heart J 2011;32:1251-1259
CrossRef | Web of Science | Medline
16Maldonado N, Kelly-Arnold A, Vengrenyuk Y, et al. A mechanistic analysis of the role of microcalcifications in atherosclerotic plaque stability: potential implications for plaque rupture. Am J Physiol Heart Circ Physiol 2012;303:H619-H628
CrossRef | Web of Science | Medline
17Narula J, Nakano M, Virmani R, et al. Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. J Am Coll Cardiol 2013;61:1041-1051
CrossRef | Web of Science | Medline
18Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993;69:377-381
CrossRef | Web of Science | Medline
19Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate intersitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 1991;11:1223-1230
CrossRef | Medline
20Rekhter MD, Zhang K, Narayanan AS, Phan S, Schork MA, Gordon D. Type I collagen gene expression in human atherosclerosis: localization to specific plaque regions. Am J Pathol 1993;143:1634-1648
Web of Science | Medline
21Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-2503
CrossRef | Web of Science | Medline
22Nikkari ST, O'Brien KD, Ferguson M, et al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995;92:1393-1398
CrossRef | Web of Science | Medline
23Herman MP, Sukhova GK, Libby P, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001;104:1899-1904
CrossRef | Web of Science | Medline
24Sukhova GK, Schonbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999;99:2503-2509
CrossRef | Web of Science | Medline
25Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995;92:1565-1569
Web of Science | Medline
26Mach F, Schoenbeck U, Bonnefoy J-Y, Pober J, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997;96:396-399
CrossRef | Web of Science | Medline
27Dutta P, Courties G, Wei Y, et al. Myocardial infarction accelerates atherosclerosis. Nature 2012;487:325-329
CrossRef | Web of Science | Medline
28Chatzizisis YS, Baker AB, Sukhova GK, et al. Augmented expression and activity of extracellular matrix-degrading enzymes in regions of low endothelial shear stress co-localize with coronary atheromata with thin fibrous caps in pigs. Circulation 2011;123:621-630
CrossRef | Web of Science | Medline
29Koskinas KC, Sukhova GK, Baker AB, et al. Thin-capped atheromata with reduced collagen content in pigs develop in coronary arterial regions exposed to persistently low endothelial shear stress. Arterioscler Thromb Vasc Biol May 2 (Epub ahead of print).
30Stone PH, Saito S, Takahashi S, et al. Prediction of progression of coronary artery disease and clinical outcomes using vascular profiling of endothelial shear stress and arterial plaque characteristics: the PREDICTION Study. Circulation 2012;126:172-181
CrossRef | Web of Science | Medline
31Aikawa M, Rabkin E, Okada Y, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 1998;97:2433-2444
CrossRef | Web of Science | Medline
32Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 2001;103:993-999
CrossRef | Web of Science | Medline
33Fukumoto Y, Deguchi JO, Libby P, et al. Genetically determined resistance to collagenase action augments interstitial collagen accumulation in atherosclerotic plaques. Circulation 2004;110:1953-1959
CrossRef | Web of Science | Medline
34Deguchi JO, Aikawa E, Libby P, et al. Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation 2005;112:2708-2715
CrossRef | Web of Science | Medline
35Schneider F, Sukhova GK, Aikawa M, et al. Matrix-metalloproteinase-14 deficiency in bone-marrow-derived cells promotes collagen accumulation in mouse atherosclerotic plaques. Circulation 2008;117:931-939
CrossRef | Web of Science | Medline
36Quillard T, Tesmenitsky Y, Croce K, et al. Selective inhibition of matrix metalloproteinase 13 (MMP-13) increases collagen content of established mouse atheromata. Arterioscler Thromb Vasc Biol 2011;31:2464-2472
CrossRef | Web of Science | Medline
37Ohayon J, Finet G, Gharib AM, et al. Necrotic core thickness and positive arterial remodeling index: emergent biomechanical factors for evaluating the risk of plaque rupture. Am J Physiol Heart Circ Physiol 2008;295:H717-H727
CrossRef | Web of Science | Medline
38Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues: implications for disorders of hemostasis and thrombosis. Am J Pathol 1989;134:1087-1097
Web of Science | Medline
39Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A 1989;86:2839-2843
CrossRef | Web of Science | Medline
40Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 2007;14:55-61
CrossRef | Web of Science | Medline
41Kubo T, Imanishi T, Takarada S, et al. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol 2007;50:933-939
CrossRef | Web of Science | Medline
42Ozaki Y, Okumura M, Ismail TF, et al. Coronary CT angiographic characteristics of culprit lesions in acute coronary syndromes not related to plaque rupture as defined by optical coherence tomography and angioscopy. Eur Heart J 2011;32:2814-2823
CrossRef | Web of Science | Medline
43Holmes DR Jr, Lerman A, Moreno PR, King SB III, Sharma SK. Diagnosis and management of STEMI arising from plaque erosion. JACC Cardiovasc Imaging 2013;6:290-296
CrossRef | Web of Science
44Braunwald E. Coronary plaque erosion: recognition and management. JACC Cardiovasc Imaging 2013;6:288-289
CrossRef | Web of Science
45Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med 2008;263:517-527
CrossRef | Web of Science | Medline
46Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol 2004;24:1309-1314
CrossRef | Web of Science | Medline
47Rajavashisth TB, Liao JK, Galis ZS, et al. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem 1999;274:11924-11929
CrossRef | Web of Science | Medline
48Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011;365:2078-2087
Free Full Text | Web of Science | Medline
49Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002;8:1257-1262[Erratum, Nat Med 2003;9:146.]
CrossRef | Web of Science | Medline
50Aikawa M, Voglic SJ, Sugiyama S, et al. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation 1999;100:1215-1222
CrossRef | Web of Science | Medline
51Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276-283
CrossRef | Web of Science | Medline
52Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004;109:Suppl 1:II-18
CrossRef | Web of Science
53Watanabe K, Sugiyama S, Kugiyama K, et al. Stabilization of carotid atheroma assessed by quantitative ultrasound analysis in nonhypercholesterolemic patients with coronary artery disease. J Am Coll Cardiol 2005;46:2022-2030
CrossRef | Web of Science | Medline
54Nakamura T, Obata JE, Kitta Y, et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. J Cardiovasc Pharmacol 2008;51:365-371
CrossRef | Web of Science | Medline
55Takarada S, Imanishi T, Kubo T, et al. Effect of statin therapy on coronary fibrous-cap thickness in patients with acute coronary syndrome: assessment by optical coherence tomography study. Atherosclerosis 2009;202:491-497
CrossRef | Web of Science | Medline
56Hattori K, Ozaki Y, Ismail TF, et al. Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS. JACC Cardiovasc Imaging 2012;5:169-177
CrossRef | Web of Science
57Tang TY, Howarth SP, Miller SR, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study: evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 2009;53:2039-2050
CrossRef | Web of Science | Medline
58Morishige K, Kacher DF, Libby P, et al. High-resolution MRI enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis. Circulation 2010;122:1707-1715
CrossRef | Web of Science | Medline
59Zhao X-Q, Dong L, Hatsukami T, et al. MR imaging of carotid plaque composition during lipid-lowering therapy: a prospective assessment of effect and time course. JACC Cardiovasc Imaging 2011;4:977-986
CrossRef | Web of Science
60Armstrong ML, Megan MB. Lipid depletion in atheromatous coronary arteries in rhesus monkeys after regression diets. Circ Res 1972;30:675-680
CrossRef | Web of Science | Medline
61Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 2005;46:1225-1228
CrossRef | Web of Science | Medline
62Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012;366:1108-1118
Free Full Text | Web of Science | Medline
63Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012;380:2007-2017
CrossRef | Web of Science | Medline
64Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-2122
Free Full Text | Web of Science | Medline
65Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-2099
Full Text | Web of Science | Medline
66The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-2267[Erratum, N Engl J Med 2012;367:189.]
Free Full Text | Web of Science | Medline
67Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE). ClinicalTrials.gov (http://clinicaltrials.gov/ct2/show/NCT00461630?term=niacin+and+laropiprant&rank=16).
68Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-1861
CrossRef | Web of Science | Medline
69The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574[Erratum, N Engl J Med 2010;362:1748.]
Free Full Text | Web of Science | Medline
70Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013;61:404-410
CrossRef | Web of Science | Medline
71White H, Held C, Stewart R, et al. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J 2010;160:655-661
CrossRef | Web of Science | Medline
72O'Donoghue ML, Braunwald E, White HD, et al. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J 2011;162:613-619
CrossRef | Web of Science | Medline
73Serruys PW, Garcia-Garcia HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008;118:1172-1182
CrossRef | Web of Science | Medline
74Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the Cardiovascular Inflammation Reduction Trial (CIRT). J Thromb Haemost 2009;7:Suppl 1:332-339
CrossRef | Web of Science | Medline
75Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011;162:597-605
CrossRef | Web of Science | Medline